InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference
November 23 2021 - 7:30AM
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:
INM), a leader in the development, manufacturing and
commercialization of rare cannabinoids, today announced that
InMed’s management team is scheduled to participate in Cowen’s 4th
Annual Cannabis Conference to be held virtually on November 29 –
December 1, 2021.
Cowen's 4th Annual Cannabis Conference
Date: November 29 - December 1, 2021
Management will be available for virtual one-on-one meetings
with institutional and corporate clients of the firm. To request
1-on-1 meetings with the Company, please contact your Cowen
institutional representative or visit the conference website at
https://www.cowen.com/conferences-and-events/4th-annual-cannabis-conference/
Cowen’s 4th Annual Cannabis Conference is a three-day
conference comprising of topical panel discussions with
C-Suite presenters, hosted by Cowen Research and Washington
Research Group analysts, and virtual one-on-one meetings.
About InMed: InMed
Pharmaceuticals is a global leader in the development,
manufacturing and commercialization of rare cannabinoids. Together
with its subsidiary, BayMedica, the Company has unparalleled
cannabinoid manufacturing capabilities to serve a spectrum of
consumer markets, including pharmaceutical and health and wellness.
InMed is a clinical-stage company developing a pipeline of rare
cannabinoid therapeutics and dedicated to delivering new treatment
alternatives to patients that may benefit from cannabinoid-based
pharmaceutical drugs. For more information,
visit www.inmedpharma.com.
Investor Contact: Colin ClancySenior Director,
Investor RelationsT: +1 604 416 0999E: cclancy@inmedpharma.com
Edison Group:Joe Green/Laine
YonkerT: +1.646.653.7030/+1.646.653.7035E: jgreen@edisongroup.com /
lyonker@edisongroup.com
Cautionary Note Regarding
Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: participating in Cowen’s 4th Annual
Cannabis Conference; delivering new therapeutic alternatives to
patients that may benefit from cannabinoid-based pharmaceutical
drugs; and developing a pipeline of cannabinoid-based
pharmaceutical drug candidates. All forward-looking information
herein is qualified in its entirety by this cautionary statement,
and InMed disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Aug 2024 to Sep 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Sep 2023 to Sep 2024